Filing Summary
Company: Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY)
Filing date: November 9, 2021. The Form 8-K reports results of operations and financial condition for the quarter and nine months ended September 30, 2021.
Business Context and Reporting Period
The filing furnishes a press release announcing the company’s quarterly and year-to-date financial results and an investor presentation. The underlying press release and presentation were not included in the provided filing text.
Financial Results and Key Metrics
- The filing does not provide clear values for revenue, net income or loss, earnings per share, cash flow, margins, debt, cash balances, liquidity, or other financial metrics.
- Financial details are incorporated by reference to Exhibit 99.1, the company’s November 9, 2021 press release.
- The filing does not provide a clear comparison with the prior comparable quarter or nine-month period.
Material Changes, Outlook, and Risks
- No specific operational or financial changes are described in the filing text beyond the announcement of the results and distribution of the investor presentation.
- Any guidance, outlook, management commentary, or business updates are contained in Exhibit 99.2 and are not available in the provided text.
- The company states that forward-looking statements involve risks and uncertainties and refers investors to the risk factors in its SEC filings, including its annual report for the year ended December 31, 2020 and subsequent filings.
- The company undertakes no general obligation to update forward-looking statements or the investor presentation.
- Exhibits 99.1 and 99.2 were furnished and are not deemed filed for purposes of Section 18 of the Exchange Act, except where specifically incorporated by reference.
Investor Verification Items
- Review Exhibit 99.1 for reported revenue, profitability, cash flow, balance-sheet liquidity, debt, and year-over-year comparisons.
- Review Exhibit 99.2 for management’s guidance, commercial performance, pipeline updates, and strategic priorities.
- Verify any non-GAAP measures and their reconciliations to the most directly comparable GAAP measures.
- Review current SEC risk factors for product concentration, regulatory, commercial, reimbursement, supply, litigation, and financing risks.